Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. (Research).
Antimicrobial resistance among enteric pathogens in developing countries is a critical area of public health concern. The usual causative agents of dysentery--shigella, campylobacter, and nontyphoidal salmonella--are becoming increasingly resistant to most agents commonly in use (1-3). The current recommendation for management of travelers' diarrhea is self-therapy with antibiotics if illness develops (4,5); fluoroquinolones are standard treatment in much of the world. Although travelers' diarrhea has traditionally been associated with enterotoxigenic Escherichia coli (ETEC), some studies from Asia have shown that campylobacter is of equal or greater importance (6-8). In the early 1990s, fluoroquinolone-resistant strains of campylobacter rapidly became prevalent in Thailand, increasing from 0% to 84% of isolates from 1990 to 1995 (1).
Azithromycin has been suggested as a replacement for quinolones for empiric treatment of travelers' diarrhea in Thailand (9). Although this drug may be a reasonable choice for travelers, its high cost precludes its use as routine treatment for dysentery in disease-endemic areas. Furthermore, the emergence in Thailand of campylobacter resistant to both quinolones and azithromycin (1) threatens the continued usefulness of both.
The seriousness of the problem has prompted calls for improved surveillance for antimicrobial resistance in developing countries, which could provide early warnings of the emergence of resistant bacterial strains (10). The prevalence of quinolone- and macrolide-resistant campylobacter in areas of Southeast Asia other than Thailand is unknown, and resistance patterns in Thailand may not apply to other countries in the region. Poorer countries such as Vietnam could benefit by avoiding a rush to newer, more expensive agents if sensitivity to older drugs could be demonstrated. Data from Vietnam relative to this issue are scarce or outdated. Surveillance data from the World Health Organization's Western Pacific Region collaboration for 1992-93 reported 0% and 2% prevalence of fluoroquinolone resistance among nontyphoidal salmonella and shigella, respectively, in Vietnam, although the numbers of isolates and shigella groups were not specified (11). Sullivan et al. (12) reported resistance rates in >3,000 isolates of shigella, salmonella, and Escherichia coli collected before 1971 from U.S. soldiers and Vietnamese residents with diarrhea; levels of resistance to tetracycline, chloramphenicol, streptomycin, and novobiocem were high, particularly among shigellae. Other than these two studies, no data have been published in English on resistance patterns in enteric diarrheal pathogens in Vietnam, and no campylobacter resistance data from this country have ever been published.
The Armed Forces Research Institute of Medical Sciences in Bangkok has been coordinating studies of the causes, epidemiology, and treatment of diarrheal diseases in Thailand and Vietnam. Antibiotic susceptibility of bacterial isolates, including shigella, ETEC, and nontyphoidal salmonella from patients with diarrhea, have been tested against the most common antibiotics, including ampicillin, tetracycline, chloramphenicol, trimethoprim-sulfamethoxazole (SXT), nalidixic acid, and fluoroquinolones. In recent years, azithromycin resistance among these pathogens, as well as the emergence of fluoroquinolone and azithromycin resistance in campylobacter species, has been monitored. A review of 15 years of data from 1981 to 1995 has been published (1). Our study further documents increasing antibiotic resistance in Thailand from 1996 to 1999 and presents resistance data from Vietnam, offering insight into regional differences between two countries that are proximal geographically, but politically and economically distant.
Source of Isolates
Bacterial isolates from studies of community-acquired diarrhea conducted in Thailand and Vietnam from 1996 to 1999 were routinely assayed for sensitivity to various antimicrobial agents. Populations under study were predominantly children <5 years of age from both urban and rural environments but also included small numbers of adult U.S. soldiers on military maneuvers in Thailand. Some isolates were obtained from asymptomatic persons. These data archives were searched initially for all isolates of shigella (other than Shigella dysenteriae 1), nontyphoidal salmonella, campylobacter, and ETEC. The lists were reviewed for the presence of duplicate isolates from the same person, and duplicates were excluded.
Enteric pathogens were cultured and identified by standard methods (13-15). ETEC isolates were identified with DNA probes. Antibiotic susceptibilities of shigella, salmonella, and ETEC were determined by the disk-diffusion method of Bauer and co-workers (16), with commercially prepared antibiotic disks containing ampicillin, tetracycline, chloramphenicol, sulfisoxazole, SXT, streptomycin, azithromycin, nalidixic acid, and ciprofloxacin. MIC agar-plate dilution methods (17,18) were used to test for nalidixic acid, ciprofloxacin, and azithromycin resistance among campylobacter species. Because of periodic shortages of reagents, not all isolates were tested to all antimicrobial agents.
Overall, 2,218 isolates were studied, 76% from Thailand and 24% from Vietnam. Pathogenic bacteria were obtained from subjects without gastrointestinal symptoms in 4.2%. Adult travelers (U.S. soldiers on maneuvers) accounted for 6.4% of Thai isolates, but none of the Vietnamese isolates. All other isolates were obtained from children <5 years of age. Sixty-one percent of Thai isolates were from an urban setting (Bangkok). All Vietnamese isolates were rural. All isolates were obtained either from cohorts enrolled in epidemiologic studies evaluating the prevalence of bacterial diarrhea pathogens or the incidence of diarrhea or from case-control studies evaluating diagnostic techniques.
Routine Susceptibility Testing for Shigella Species Other than S. dysenteriae 1, ETEC, and Salmonella
From Thailand, 175 shigella (65% S. sonnei, 32% S. flexneri), 696 nontyphoidal salmonella, and 203 ETEC isolates were studied during the 3-year period. From Vietnam, 305 shigella (18% S. sonnei, 71% S. flexneri), 30 salmonella, and 113 ETEC isolates were studied (Table 1).
Among shigella, high levels of resistance to tetracycline and SXT were noted in both Thailand and Vietnam. Significantly less resistance was noted among Thai isolates to ampicillin (29% vs. 77%, p<0.05) and chloramphenicol (21% vs. 64%, p<0.05). Sorting by shigella group showed that nearly all the difference between Thai and Vietnamese isolates was accounted for by differences in the prevalence and susceptibility of S. sonnei compared with the more resistant S. flexneri strains. In Thailand, S. sonnei was almost all susceptible to ampicillin and chloramphenicol; in Vietnam, S. sonnei was more commonly resistant to these agents.
ETEC isolates demonstrated high-level resistance in both countries to ampicillin, SXT, tetracycline, and sulfisoxazole, but chloramphenicol resistance was relatively low in both countries. In contrast, nontyphoidal salmonella from Thailand had consistently and substantially higher levels of resistance to all agents, compared with those from Vietnam. Serogroup B salmonellae in Thailand were generally more resistant than other serogroups, except for serogroup C isolates, which were relatively more resistant to nalidixic acid and azithromycin.
Quinolone and Macrolide Resistance among Shigella, Salmonella, and ETEC
Resistance to nalidixic acid was rare among shigella (< 1%) and ETEC (3%) in both Thailand and Vietnam but was more common among Thai salmonella (21%). Resistance to ciprofloxacin was documented in <1% of isolates, including two salmonellae (from Thailand) and four ETEC (three from Thailand, one from Vietnam). No shigellae were resistant to ciprofloxacin in either country (Table 1).
With the exception of S. sonnei, azithromycin resistance was found in [less than or equal to] 8% of shigella, salmonella, and ETEC, with no significant difference between Vietnam and Thailand. Azithromycin resistance was present in 28% of S. sonnei isolates from Vietnam but only 2% of Thai isolates (p<0.05).
Resistance of Campylobacter to Quinolones and Macrolides
We studied 608 campylobacter isolates from Thailand and 88 from Vietnam. Resistance to nalidixic acid (73% vs. 7% respectively, p<0.05) and ciprofloxacin (77% vs. 7% respectively, p<0.05) differed markedly between Thai and Vietnamese isolates. Among Vietnamese isolates, quinolone resistance was predominantly among Campylobacter coli rather than C. jejuni, but rates among Thai isolates were similar between species. Resistance to azithromycin was low in Thailand (6%), where it predominated among C. coli. No azithromycin resistance was present in Vietnamese isolates (Table 1).
Co-Resistance to Quinolones and Macrolides among Campylobacters and Salmonellae
Vietnamese isolates of campylobacter were uniformly sensitive to azithromycin, so we were unable to examine correlations with quinolone resistance. Among Thai isolates, however, azithromycin resistance correlated with resistance to ciprofloxacin (p=0.007) (Table 2). Among campylobacter tested to both these agents, all isolates (n=29) that were resistant to azithromycin were also resistant to ciprofloxacin. Based on the 23% prevalence of ciprofloxacin sensitivity among azithromycin-susceptible strains, a similar rate of discordance among azithromycin-resistant strains would be expected if these resistance patterns were independent. Co-resistant isolates included both C. coli (n=22) and C. jejuni (n=7), were composed of multiple serogroups and resistance profiles, were present in both travelers and indigenous Thais, and were dispersed geographically around Thailand and temporally over the 4 years of data; therefore, they are not likely to be clonally related. These isolates were significantly more likely to be C. coli (76%) than were azithromycin sensitive isolates (C. coli 15%; p<0.001).
Too few salmonellae were resistant to ciprofloxacin for analysis of cross-resistance; however, among isolates tested for resistance to both the first-generation quinolone nalidixic acid and azithromycin (Table 3), a highly significant correlation was found (p<0.001). Based on the 31% prevalence of nalidixic acid resistance among azithromycin sensitive strains, a similar proportion would be expected among azithromycin-resistant strains if the two were independent, rather than the 80% documented.
Multiple-Antibiotic Resistance among Shigellae, Salmonellae, and ETEC
Multiple resistance to ampicillin, chloramphenicol, tetracycline, SXT, and streptomycin was quite common among shigella isolates in both Thailand and Vietnam, but was significantly more so in Vietnam (46% vs. 21%, p<0.001). Lower levels of multiple resistance to these drugs were noted among salmonella and ETEC isolates from both countries (3% to 7%).
Association between Symptoms and Prevalence of Antimicrobial Resistance
No association was found with presence or absence of gastrointestinal symptoms among isolates from Vietnam or among campylobacter or shigella isolates from Thailand. Thai ETEC and salmonellae that were isolated from participants with symptoms were significantly more likely to be resistant across the spectrum of antimicrobial agents studied (Mantel-Haensel summary chi square p=0.01 and p<0.01, respectively).
This study points out several new findings relative to antimicrobial resistance among enteric pathogens in Southeast Asia. We have documented the existence of quinolone resistance among campylobacter, shigella, and ETEC in Vietnam. If the pattern of campylobacter in Thailand holds true in Vietnam, one can expect rapidly increasing resistance rates to quinolones over the next few years in this genus. The reasons for the marked difference in resistance rates to this class of drugs between the two countries are unknown but likely reflect differences in human and veterinary use of fluoroquinolones.
Quinolone resistance among nontyphoidal salmonella was not seen in isolates from Vietnam, and ciprofloxacin resistance remains rare among this species in Thailand; however, progressive resistance to nalidixic acid among Thai isolates is cause for concern. Hoge (1) documented steadily increasing nalidixic acid resistance among nontyphoidal salmonellae in Thailand, from <1% in 1991-92 to 4% in 1993-94 and 9% in 1995. We documented 21% resistance in this genus during 1996 to 1999, more than double 1995 rates (chi square for trend, p<0.001). As resistance to nalidixic acid due to first-step resistance mutations is generally thought to precede resistance to fluoroquinolones (19), close continued monitoring of resistance rates to both these drugs among nontyphoidal salmonellae is warranted.
Although cases of infections due to macrolide- and fluoroquinolone-resistant campylobacter have been reported, these have usually been among immunocompromised persons who have received multiple antibiotics (20-22). Our study is the first to document a statistical correlation between these two resistance patterns among a large number of community-acquired enteric isolates. Although the prevalence of azithromycin resistance remains relatively low in Thailand (6%) while ciprofloxacin resistance is high (77%), our study had sufficient power to confirm that the 100% correlation between resistance to these two agents was not likely due to chance. Previous studies of smaller numbers of azithromycin-resistant isolates from Thailand also support this 100% correlation (1,7,9). Resistance to quinolones is generally mediated by mutations in the chromosomal genes for DNA gyrase or topoisomerase IV, which are targets of action by the quinolone class, or less commonly in genes responsible for membrane flux of the drug (19), including plasmid-mediated enhanced efflux mechanisms. Resistance to macrolides most commonly results from mutations in the genes encoding ribosomal proteins but has also been associated with decreased permeability of the cell envelope in enterobacteriaceae, including plasmid-mediated mechanisms (21,23). Cross-resistance due to decreased membrane permeability has been documented between quinolones and chloramphenicol, trimethoprim, tetracycline, and cefoxitin, but not macrolides (19). Possible novel cross-resistance mechanisms in these isolates deserve to be more closely evaluated, as a common plasmid-mediated mechanism would increase the likelihood of horizontal spread.
Although resistance to quinolones among campylobacters from Vietnam was markedly lower than that from Thailand, multidrug resistance to other agents among Vietnamese shigella isolates was significantly higher than among Thai isolates, perhaps reflecting differences in human use patterns. In Vietnam in 1997, ampicillin, SXT, tetracycline, and chloramphenicol were the antimicrobial agents most commonly dispensed over the counter (24). Thai data from 10 years earlier (1987) document common dispensing of the same four drugs by Bangkok pharmacists (25), although fluoroquinolones were more frequently used for children with diarrhea admitted to Thai hospitals during 1990-1992 (26), and quinolones have likely become increasingly used in the decade since. Our data suggest that ampicillin, SXT, tetracycline, and chloramphenicol have no reasonable role in the empiric treatment of dysentery in Vietnam and should be replaced with quinolones or macrolides for this indication. Shigellae in Thailand are uniformly sensitive to quinolones, but dysentery and travelers' diarrhea in Thailand are predominantly caused by quinolone-resistant campylobacter rather than shigella and are thus better treated empirically with macrolides. Although ampicillin resistance among Thai shigellae was stable during the 4 years of this study, data from the preceding 15 years (1) demonstrate that resistance has decreased linearly (chi square for trend, p<0.001), perhaps reflecting overall reduced human use of this drug in Thailand as other agents have become more popular.
Concern in Thailand over the possibility of increasing rates of resistance to azithromycin developing in campylobacter species is not yet borne out by our study. Hoge (1) demonstrated azithromycin resistance rates of 15% in 1994 and 7% in 1995 among campylobacters. Our data show 7% resistance among isolates from 1996 to 1999, failing to confirm an upward trend.
Limitations of our study include the fact that isolates were obtained from multiple populations, both indigenous and U.S. military, in Thailand. However, the rates documented likely reflect overall resistance among human isolates. Additionally, the populations under study in Vietnam were all from areas around Hanoi and therefore do not necessarily reflect resistance rates seen in other parts of Vietnam.
This study highlights the need to be aware of regionally specific resistance rates to avoid inappropriate antibiotic use. Additionally, given the evidence for progressive resistance to the quinolone class and co-resistance between quinolones and azithromycin among salmonellae and campylobacters, the need to develop newer classes of antibiotics to treat dysentery and travelers' diarrhea is apparent. More efficient use of antimicrobial agents, for example, avoidance of antimicrobial therapy for acute noncholera watery diarrhea and use of effective data-based antimicrobial choices for dysentery, would likely help limit the development of resistance, although the impact of these measures would be offset by the widespread availability of antimicrobial agents over the counter in both these countries. Effective vaccines against the major causes of bacterial diarrhea are being developed but are still years away from commercial production. Parallel drug development efforts are required.
Table 1. Antibiotic resistance patterns among selected enteric pathogens in Thailand and Vietnam, 1996-999 (a) AM CM SXT Pathogen Site N %R N %R N %R ETEC Thailand 203 54 203 13 203 51 Vietnam 113 67 113 17 113 63 Salmonella (all) Thailand 696 28 696 26 696 37 Vietnam 30 3 30 7 30 10 Group B Thailand 258 49 258 45 258 67 Vietnam 6 0 6 0 6 0 Group C Thailand 192 5 192 13 192 12 Vietnam 1 0 1 0 1 0 Group D Thailand 68 31 68 31 68 38 Vietnam 7 0 7 14 7 14 Group E Thailand 133 24 133 11 133 16 Vietnam 14 0 14 0 14 7 Other Thailand 45 9 45 11 45 16 Vietnam 2 50 2 50 2 50 Shigella (all) Thailand 175 29 175 21 175 90 Vietnam 305 77 305 64 305 78 Group A Thailand 3 0 3 0 3 0 Vietnam 6 50 6 17 6 50 Group B Thailand 56 82 56 61 56 86 Vietnam 216 84 216 74 216 83 Group C Thailand 2 0 2 0 2 0 Vietnam 28 54 28 46 28 68 Group D Thailand 114 4 114 3 114 97 Vietnam 55 62 55 36 55 67 Campylobacter Thailand ND ND ND Vietnam ND ND ND C. jejuni Thailand ND ND ND Vietnam ND ND ND C. coli Thailand ND ND ND Vietnam ND ND ND NA CIP Pathogen Site N %R N %R ETEC Thailand 203 3 203 2 Vietnam 112 < 1 113 < 1 Salmonella (all) Thailand 696 21 696 < 1 Vietnam 30 0 30 0 Group B Thailand 258 23 258 < 1 Vietnam 6 0 6 0 Group C Thailand 192 33 192 0 Vietnam 1 0 1 0 Group D Thailand 68 18 68 0 Vietnam 7 0 7 0 Group E Thailand 133 4 133 0 Vietnam 14 0 14 0 Other Thailand 45 4 45 0 Vietnam 2 0 2 0 Shigella (all) Thailand 175 < 1 175 0 Vietnam 305 < 1 305 0 Group A Thailand 3 0 3 0 Vietnam 6 0 6 0 Group B Thailand 56 0 56 0 Vietnam 216 < 1 216 0 Group C Thailand 2 0 2 0 Vietnam 28 0 28 0 Group D Thailand 114 < 1 114 0 Vietnam 55 0 55 0 Campylobacter Thailand 608 73 531 77 Vietnam 88 7 85 7 C. jejuni Thailand 489 72 426 75 Vietnam 71 1 69 1 C. coli Thailand 108 75 94 80 Vietnam 17 29 16 31 TE AZM Pathogen Site N %R N %R ETEC Thailand 203 43 68 4 Vietnam 113 65 37 3 Salmonella (all) Thailand 695 59 284 5 Vietnam 30 13 19 0 Group B Thailand 258 77 82 1 Vietnam 6 0 3 0 Group C Thailand 191 62 101 12 Vietnam 1 0 1 0 Group D Thailand 68 46 28 4 Vietnam 7 1 4 0 Group E Thailand 133 18 52 5 Vietnam 14 7 10 0 Other Thailand 45 18 21 5 Vietnam 2 100 1 0 Shigella (all) Thailand 175 91 68 2 Vietnam 305 80 233 8 Group A Thailand 3 33 0 NA Vietnam 6 50 6 0 Group B Thailand 56 96 18 0 Vietnam 216 87 165 5 Group C Thailand 2 0 0 NA Vietnam 28 75 22 0 Group D Thailand 114 92 50 2 Vietnam 55 60 40 28 Campylobacter Thailand ND 520 6 Vietnam ND 62 0 C. jejuni Thailand ND 415 2 Vietnam ND 48 0 C. coli Thailand ND 94 26 Vietnam ND 14 0 (a) AM = ampicillin; CM = chloramphenicol; SXT = tirimethoprim-isulfamethoxazole; NA = nalidixic acid; CIP = ciprofloxacin; TE = etetracyclinee; AZM = azithromycin; ND = not done; %R = percent resistant; NA = not applicable. Table 2. Co-resistance (a) to azithromycin (AZM) and ciprofloxacin (CIP) among campylobacter isolates in Thailand, 1996-1999 AZM R (a) S CIP R 29 (b) 358 S 0 109 Table 3. Co-resistance (a) to azithromycin (AZM) and nalidixic acid (NA) among salmonella isolates in Thailand AZM R (a) S NA R 12 (b) 55 S 3 122
We thank the scientists, technicians, and staff of the National Institute of Hygiene and Epidemiology in Hanoi and the Armed Forces Institute of Medical Sciences in Bangkok for their microbiologic expertise and assistance with study conduct, specimen collection, and data processing. We also thank David Taylor and Fernando Guerena for their thoughtful reviews of and recommendations for the manuscript.
Financial support was provided by the U.S. Army Medical Research and Materiel Command and Global Emerging Infectious Diseases Program.
(1.) Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998;26:341-5.
(2.) Heikkila E, Siitonen A, Jahkola M, Fling M, Sundstrom L, Huovinen P. Increase of trimethoprim resistance among shigella species, 1975-1988: analysis of resistance mechanisms. J Infect Dis 1990;161:1242-8.
(3.) Tauxe RV, Puhr ND, Wells JG, Hargrett-Bean N, Blake PA. Antimicrobial resistance of shigella isolates in the USA: the importance of international travelers. J Infect Dis 1990;162:1107-11.
(4.) Dupont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993;328:1821-7.
(5.) DuPont HL. Editorial response: antimicrobial-resistant campylobacter species--a new threat to travelers to Thailand. Clin Infect Dis 1995;21:542-3.
(6.) Beecham HJ, LeBron CI, Echeverria P. Short report: impact of traveler's diarrhea on United States troops deployed to Thailand. Am J Trop Med Hyg 1997;57:699-701.
(7.) Murphy GS, Echeverria P, Jackson LR, Arness MK, LeBron CI, Pitarangsi C. Ciprofloxacin and azithromycin-resistant campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin Infect Dis 1996;22:868-9.
(8.) Echeverria P, Jackson LR, Hoge CW, Arness MK, Dunnavant GR, Larsen RR. Diarrhea in US troops deployed to Thailand. J Clin Microbiol 1993;31:3351-2.
(9.) Kuschner RA, Trofa AF, Thomas RJ, Hoge CW, Pitarangsi C, Amato S, et al. Use of azithromycin for the treatment of campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995;21:536-41.
(10.) Hart CA, Kariuki S. Antimicrobial resistance in developing countries. BMJ 1998;317:647-50.
(11.) Turnidge J. Epidemiology of quinolone resistance. Drugs 1995;49 Suppl 2:43-7.
(12.) Sullivan TJ, Nhu-Tuan NT. Bacterial enteropathogens in the Republic of South Vietnam. Mil Med 1971;136:1-6.
(13.) Echeverria P, Taylor DN, Lexsomboon U, Bhaibulaya M, Blacklow NR, Tamura K, et al. Case-control study of endemic diarrheal disease in Thai children. J Infect Dis 1989;159:543-8.
(14.) Echeverria P, Sethabutr O, Pitarangsi C. Microbiology and diagnosis of infections with shigella and enteroinvasive Escherichia coli. Rev Infect Dis 1991;13 Suppl 4:S220-5.
(15.) Echeverria P, Hoge CW, Bodhidatta L, Tungtaem C, Herrmann J, Imlarp S, et al. Etiology of diarrhea in a rural community in western Thailand: importance of enteric viruses and enterovirulent Escherichia coli. J Infect Dis 1994;169:916-8.
(16.) Bauer AW, Kirby WM, Sherris JC, Turch M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493-6.
(17.) Tenover FC, Baker CN, Fennell CL, Ryan CA. Antimicrobial resistance in campylobacter species. In: Nachamikin I, Blaser MJ, Tompkins LS, editors. Campylobacter jejuni: current status and future trends. Washington: American Society for Microbiology; 1992. p. 66-73.
(18.) National Committee for Clinical Laboratory Standards. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. NCCLS document M7-A3. Villanova (PA): The Committee; 1993.
(19.) Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000;30:243-54.
(20.) Tee W, Mijch A, Wright E, Yung A. Emergence of multidrug resistance in Campylobacter jejuni isolates from three patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:634-8.
(21.) Burnens AP, Heitz M, Brodard I, Nicolet J. Sequential development of resistance to fluoroquinolones and erythromycin in an isolate of Campylobacter jejuni. Zentralbl Bakteriol 1996;283:314-21.
(22.) Lu PL, Hsueh PR, Hung CC, Chang SC, Luh KT, Lee CY. Bacteremia due to campylobacter species: high rate of resistance to macrolide and quinolone antibiotics. J Formos Med Assoc 2000;99:612-7.
(23.) Steinbigel NH. Erythromycin, lincomycin, and clindamycin. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone; 1990. p. 309.
(24.) Van Duong D, Binns CW, Van Le T. Availability of antibiotics as over-the-counter drugs in pharmacies: a threat to public health in Vietnam. Trop Med Int Health 1997;2:1133-9.
(25.) Thamlikitkul V. Antibiotic dispensing by drug store personnel in Bangkok, Thailand. J Antimicrob Chemother 1988;21:125-31.
(26.) Visitsunthorn N, Komolpis P. Antimicrobial therapy in Plesiomonas shigelloides-associated diarrhea in Thai children. Southeast Asian J Trop Med Public Health 1995;26:86-90.
Address for correspondence: Daniel W. Isenbarger, 7543 Spring Lake Dr., #D-1, Bethesda, MD 20817, USA; fax: 202-782-3813; e-mail: firstname.lastname@example.org
Daniel W. Isenbarger, * Charles W. Hoge, ([dagger]) Apichai Srijan, * Chittima Pitarangsi, * Niyada Vithayasai, ([double dagger]) Ladaporn Bodhidatta, * Kimberly W. Hickey, ([section]) and Phung Dec Cam ([paragraph])
* Armed Forces Research Institute of Medical Science, Bangkok, Thailand; ([dagger]) Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; ([double dagger]) Queen Sirikit National Institute of Child Health, Bangkok, Thailand;. ([section]) Tripler Army Medical Center, Honolulu, Hawaii, USA; and ([paragraph]) National Institute of Hygiene and Epidemiology, Hanoi, Vietnam
Dr. Isenbarger is a physician and epidemiologist in the Department of Enteric Infections, Walter Reed Army Institute of Research. His professional interests include clinical internal medicine, epidemiology of diarrheal disease in developing countries, and clinical trials of enteric vaccine candidates.
|Printer friendly Cite/link Email Feedback|
|Author:||Cam, Phung Dac|
|Publication:||Emerging Infectious Diseases|
|Article Type:||Statistical Data Included|
|Date:||Feb 1, 2002|
|Previous Article:||Clinical significance and epidemiology of NO-1, an unusual bacterium associated with dog and cat bites. (Research).|
|Next Article:||Erratum vol. 8, no. 1.|